Jazz Pharmaceuticals

The Rare and COMPLEX Epilepsies Rights Charter is a not-for-profit collaboration between Jazz Pharmaceuticals, UCB, Epilepsy plus alliance‑E+A, and the INTERNATIONAL BUREAU FOR EPILEPSY (IBE) which has been initiated and equally funded by Jazz Pharmaceuticals and UCB Pharma. Together, with our partners, we are pleased to welcome a distinguished and diverse group of experts to the steering committee. Their lived experience and professional insight will guide the creation of the Rare and COMPLEX Epilepsies Continuity of Care Rights Charter.  People living with rare and complex epilepsies in Europe often do not receive adequate continuity of care when transitioning from pediatric to adult services. These gaps can leave patients and carers feeling vulnerable and increase the risk of clinical deterioration.  Poorly managed continuity of care in people with rare and complex epilepsies is associated with poorer medical and psychosocial outcomes, due to many reasons including:   • Increased hospitalization and reliance on emergency department services • Reduced quality of life • Increased disengagement from care   • Psychosocial deterioration • Difficulty integrating into adult systems   The Rare and COMPLEX Epilepsies Continuity of Care Rights Charter aims to promote consistency across Europe, so that every child and adult with rare and complex epilepsy has a supported experience when moving from pediatric to adult care. We are proud to be guided by a steering committee whose professional insight will guide the creation of a charter that reflects the realities of care and the aspirations of families across Europe. 

On International Clinical Trials Day, we recognize the people who make medical innovation possible. At Jazz, our clinical research begins with needs of patients and their families. We have an unwavering commitment to improving care for people living with rare diseases through ongoing clinical development programs, and that progress is only possible because of those who participate in clinical trials, the loved ones who support them and the investigators and research teams who bring science to life with compassion and rigor. We are grateful for your contributions and honored to work alongside you to advance science and address unmet medical needs. Learn more about our clinical trials: https://lnkd.in/eRatjefp 

"I can't die, I'm busy." This powerful phrase defined Jace's approach to life after he was diagnosed with diffuse midline #glioma (DMG) – a rare and aggressive brain tumor. Instead of focusing on limitations, he channeled his energy into making an impact by connecting people, encouraging those around him and advocating for continued progress in childhood cancer care.      Inspired by her son's impact, Lisa and her family continue to build upon his legacy to help expand research, advocacy and treatment options for other families facing rare brain cancers. See their story in honor of #BrainCancerAwarenessMonth: https://bit.ly/4nygGOp

#TuberousSclerosisComplex (TSC) is a rare genetic disorder that causes non-cancerous tumors to develop in multiple organs across the body – including the brain. The neurological changes driven by TSC can have a significant impact on daily life including developmental delays and cognitive impairment, as well as neuro-psychiatric challenges. Despite this, its highly variable presentation means diagnosis is often delayed – and in some cases TSC remains unrecognized. On #TSCGlobalDay and beyond, we are committed to raising awareness of TSC and advancing meaningful innovation to help address unmet needs for people living with this complex condition.

Neuro-oncology is an important area of research and development at Jazz, and one where we believe bold science can make the most difference for patients and their families.     From rare pediatric brain tumors like H3 K27M-mutant diffuse midline glioma (DMG) to other aggressive central nervous system cancers, we’re committed to going where the science leads and where patient need is greatest.    This #BrainTumorAwarenessMonth, we’re joining #GrayMay to reaffirm our dedication to the patients, caregivers and communities who inspire this work every day. Learn more about our work in rare brain cancers: https://bit.ly/432AUq2   #BTAM #BrainCancerAwarenessMonth 

We’re honored to be recognized for the third consecutive year by the Association of Strategic Alliance Professionals, winning the 2025 ASAP Alliance Excellence Award for Innovative Collaboration. Congratulations to Katherine Kendrick, CSAP and our alliance management team who accepted the award at the ASAP Global Summit this week. This recognition reflects an innovative and rigorous process of alliance partner financial health assessment designed to protect strategic alliance value and drive effective corporate and alliance decision making. Our alliance management team builds and sustains high-performing partnerships with the joint goal of supporting patients and their families. Learn more about the award: https://lnkd.in/e8tWhnKK

Many patients with diffuse midline #glioma (DMG), a rare and aggressive brain tumor, face a difficult reality: delayed diagnoses and limited access to the specialized care they need.     In recognition of #BrainCancerAwarenessMonth, hear from Amanda Saratsis, MD, Senior Director, Global Medical Affairs Oncology at Jazz as she shares insights on the need for early molecular diagnostic testing in patients with rare brain cancers like DMG: https://bit.ly/42Q0wGG

#News for U.S. media and investors: Jazz announces first quarter 2026 financial results $JAZZ: https://bit.ly/49v7VyN

Congratulations to our 2026 Healthcare Businesswomen’s Association (HBA) Luminary, Kristin Bhavnani and Rising Star, Eloho Ojabunor and to Rick Winningham, our lead independent director of the Jazz Pharmaceuticals Board of Directors, as the HBA Honorable Mentor of the Year for 2026. Their leadership, impact, and commitment to advancing women across healthcare were recognized last week during the HBA Global Ascension Leadership Experience. We’re proud to see their achievements acknowledged among such an inspiring community of industry leaders. A special congratulations to all members of the 2026 HBA Rising Stars and Luminaries class—an incredible group shaping the future of healthcare. #AscendWithHBA #HBAImpact

#News for U.S. media and investors: We’re excited to share that the U.S. FDA has accepted and granted Priority Review for the supplemental Biologic License Application (sBLA) for our potential treatment for HER2+ unresectable locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). Learn more: https://bit.ly/4sYvF5s   Backed by Phase 3 data, this milestone highlights an important step forward in our ongoing efforts to help redefine care for people living with this aggressive, difficult-to-treat cancer.